First‐in‐human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti‐CD40 monoclonal antibody

Blockade of CD40–CD154 pathway interactions suppresses ectopic lymphoid structures and inhibits pathology in the NOD/ShiLtJ mouse model of Sjögren’s syndrome

(2019) Grazyna Wieczorek et al.   ANNALS OF THE RHEUMATIC DISEASES

Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody

(2018) Jacinda Ristov et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases

(2017) Fredrik N. Albach et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

A Novel, Blocking, Fc-Silent Anti-CD40 Monoclonal Antibody Prolongs Nonhuman Primate Renal Allograft Survival in the Absence of B Cell Depletion

(2015) F. Cordoba et al.   AMERICAN JOURNAL OF TRANSPLANTATION

The association of CD40 polymorphisms with CD40 serum levels and risk of systemic lupus erythematosus

(2015) Jian-Ming Chen et al.   BMC GENETICS

Pharmacokinetics and Pharmacodynamics of ASKP1240, a Fully Human Anti-CD40 Antibody, in Normal and Renal Transplanted Cynomolgus Monkeys

(2014) Anlun Ma et al.   TRANSPLANTATION

A Phase 1, Randomized Ascending Single-Dose Study of Antagonist Anti-Human CD40 ASKP1240 in Healthy Subjects

(2013) R. Goldwater et al.   AMERICAN JOURNAL OF TRANSPLANTATION

The Antibody Drug Absorption Following Subcutaneous or Intramuscular Administration and Its Mathematical Description by Coupling Physiologically Based Absorption Process with the Conventional Compartment Pharmacokinetic Model

(2013) Liang Zhao et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The Immunologic Functions of the Neonatal Fc Receptor for IgG

(2012) Timo Rath et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification

(2012) Lambertus A. Peletier et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

The pattern of inflammatory/anti-inflammatory cytokines and chemokines in type 1 diabetic patients over time

(2010) Antonios Chatzigeorgiou et al.   ANNALS OF MEDICINE

On Setting the First Dose in Man: Quantitating Biotherapeutic Drug-Target Binding through Pharmacokinetic and Pharmacodynamic Models

(2009) Philip J. Lowe et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies

(2009) Patrick Y Muller et al.   CURRENT OPINION IN BIOTECHNOLOGY

Dynamics of target-mediated drug disposition

(2009) Lambertus A. Peletier et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

CD40 Expression and its Association with Low-grade Inflammation in a Greek Population of Type 1 Diabetic Juveniles: Evidence for Differences in CD40 mRNA Isoforms Expressed by Peripheral Blood Mononuclear Cells

(2009) A. E. Chatzigeorgiou et al.   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

The effect of anti-CD40 ligand in immune thrombocytopenic purpura

(2008) Vivek L. Patel et al.   BRITISH JOURNAL OF HAEMATOLOGY